Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash from Operations (2016 - 2025)

Enanta Pharmaceuticals' Cash from Operations history spans 14 years, with the latest figure at 11699000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 30.37% year-over-year to 11699000.0; the TTM value through Dec 2025 reached 14170000.0, up 79.92%, while the annual FY2025 figure was 19272000.0, 75.53% up from the prior year.
  • Cash from Operations reached 11699000.0 in Q4 2025 per ENTA's latest filing, down from 6489000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 17506000.0 in Q2 2025 to a low of 35641000.0 in Q4 2022.
  • Average Cash from Operations over 5 years is 17638850.0, with a median of 16167500.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: crashed 557.44% in 2021, then soared 218.48% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 13271000.0 in 2021, then crashed by 168.56% to 35641000.0 in 2022, then increased by 29.89% to 24988000.0 in 2023, then soared by 32.76% to 16801000.0 in 2024, then surged by 30.37% to 11699000.0 in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Cash from Operations are 11699000.0 (Q4 2025), 6489000.0 (Q3 2025), and 17506000.0 (Q2 2025).